Krystal Biotech (NASDAQ:KRYS) Trading Down 2.9% on Insider Selling

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) shares fell 2.9% on Friday after an insider sold shares in the company. The stock traded as low as $79.45 and last traded at $79.46. 25,424 shares were traded during trading, a decline of 87% from the average session volume of 190,119 shares. The stock had previously closed at $81.82.

Specifically, Director Dino A. Rossi sold 40,000 shares of the firm’s stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $83.25, for a total transaction of $3,330,000.00. Following the sale, the director now owns 83,691 shares in the company, valued at approximately $6,967,275.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Dino A. Rossi sold 40,000 shares of the stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $83.25, for a total transaction of $3,330,000.00. Following the transaction, the director now owns 83,691 shares of the company’s stock, valued at approximately $6,967,275.75. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Suma Krishnan sold 1,700 shares of the stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $80.33, for a total transaction of $136,561.00. Following the transaction, the insider now directly owns 1,706,201 shares in the company, valued at approximately $137,059,126.33. The disclosure for this sale can be found here. In the last quarter, insiders have sold 110,844 shares of company stock worth $9,034,599. 17.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on KRYS. The Goldman Sachs Group raised shares of Krystal Biotech from a “neutral” rating to a “buy” rating and raised their price target for the stock from $79.00 to $124.00 in a report on Tuesday. Chardan Capital reissued a “buy” rating and issued a $133.00 price target on shares of Krystal Biotech in a report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $119.00 price target on shares of Krystal Biotech in a report on Tuesday. Finally, Guggenheim reissued a “buy” rating and issued a $101.00 price target on shares of Krystal Biotech in a report on Tuesday.

Krystal Biotech Trading Down 3.4 %

The business’s 50 day moving average price is $79.43 and its two-hundred day moving average price is $75.18. The stock has a market cap of $2.04 billion, a P/E ratio of -14.34 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS – Get Rating) last announced its earnings results on Monday, February 27th. The company reported ($1.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.01. As a group, analysts expect that Krystal Biotech, Inc. will post -5.52 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. lifted its position in Krystal Biotech by 4.9% during the 1st quarter. BlackRock Inc. now owns 1,683,511 shares of the company’s stock valued at $112,020,000 after acquiring an additional 78,015 shares during the period. Avoro Capital Advisors LLC lifted its position in Krystal Biotech by 10.6% during the 4th quarter. Avoro Capital Advisors LLC now owns 1,410,000 shares of the company’s stock valued at $111,700,000 after acquiring an additional 135,000 shares during the period. Lord Abbett & CO. LLC lifted its position in Krystal Biotech by 5.5% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,278,022 shares of the company’s stock valued at $101,245,000 after acquiring an additional 66,081 shares during the period. Vanguard Group Inc. lifted its position in Krystal Biotech by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,096,132 shares of the company’s stock valued at $76,400,000 after acquiring an additional 26,844 shares during the period. Finally, Frazier Life Sciences Management L.P. lifted its position in Krystal Biotech by 26.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,095,407 shares of the company’s stock valued at $71,924,000 after acquiring an additional 229,157 shares during the period. 80.80% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

(Get Rating)

Krystal Biotech, Inc is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases.